Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioScience Health InnovationsBHIC -20.00%49 Cash Ratio is 2.37 as of Jun. 2026, which is 21% below its 10-year median of 3.00. GuruFocus rates BHIC with a GF Score™ of 49/100 and a GF Value™ of $121.85 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 666 Healthcare Providers & Services companies, BioScience Health Innovations ranks better than 82.88% on this metric.
BioScience Health Innovations has a Cash Ratio of 2.37. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for BioScience Health Innovations's Cash Ratio or its related term are showing as below:
BHIC'
s Cash Ratio Range Over the Past 10 Years
Min: 0.11 Med: 3 Max: 17
Current: 2.37
During the past 7 years, BioScience Health Innovations's highest Cash Ratio was 17.00. The lowest was 0.11. And the median was 3.00.
BHIC's Cash Ratio is ranked better than 82.88% of 666
companies
in the Healthcare Providers & Services industry
Industry Median: 0.58
vs BHIC: 2.37
BioScience Health Innovations (OTCPK:BHIC) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
BioScience Health Innovations Cash Ratio Related Terms
BioScience Health Innovations Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioScience Health Innovations Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's Cash Ratio distribution charts can be found below:
* The bar in red indicates where BioScience Health Innovations's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioScience Health Innovations (BHIC) has a Cash Ratio of 2.37 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BioScience Health Innovations and its competitors. This is 21% below median its historical median of 3.00. Over the past decade, BioScience Health Innovations' Cash Ratio has ranged from 0.11 to 17.00. According to the industry distribution chart, BioScience Health Innovations ranks #114 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 17.1%.
Is BioScience Health Innovations' Cash Ratio too high?
BioScience Health Innovations' current Cash Ratio of 2.37 is 21% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 17.00. The Healthcare Providers & Services industry median Cash Ratio is 0.58. BioScience Health Innovations' value of 2.37 is 308.6% above this industry median. Based on the distribution chart, BioScience Health Innovations ranks #114 out of 666 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, BioScience Health Innovations has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' Cash Ratio compare to PETS and SCNX?
According to the Healthcare Providers & Services industry distribution chart, BioScience Health Innovations ranks #114 out of 666 companies for Cash Ratio. This places BioScience Health Innovations in the top 17% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.58. BioScience Health Innovations' value of 2.37 is 308.6% above this benchmark. Historically, BioScience Health Innovations' own Cash Ratio has ranged from 0.11 to 17.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 0.58, BioScience Health Innovations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.58, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioScience Health Innovations's current Cash Ratio of 2.37 is 308.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on BioScience Health Innovations and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioScience Health Innovations's current Cash Ratio is 2.37, which is 21% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $121.85, compared to a current price of $4.00 — trading 96.7% below its estimated fair value. The current Cash Ratio is 2.37, which is 21% below median its 10-year median of 3.00 and 308.6% above the Healthcare Providers & Services industry median of 0.58. BioScience Health Innovations' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current Cash Ratio is 2.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioScience Health Innovations (BHIC) Overvalued in 2026?
Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued.
The current stock price of $4.00 is trading 96.7% below its estimated GF Value™ of $121.85.
GuruFocus considers BioScience Health Innovations to be Possible Value Trap.
Key valuation signals for BHIC:
Cash Ratio: 2.37 (21% below median its 10-year median of 3.00)
GF Value™: $121.85 vs. price of $4.00 (96.7% below fair value)
Industry Position: 308.6% above the Healthcare Providers & Services median (#114 of 666)
No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
49GF Score
Get the complete analysis for BHIC
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHIC has been successfully added to your 
